New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

by NRG OncologyResults from the Phase III NRG Oncology NRG-GU003 clinical trial comparing hypofractioned post-prostatectomy radiotherapy (HYPORT) to conventionally fractioned post-prostatectomy radiot
Oncology March 30,2024
Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings

by NRG OncologyResults from the Phase III NRG Oncology NRG-GU003 clinical trial comparing hypofractioned post-prostatectomy radiotherapy (HYPORT) to conventionally fractioned post-prostatectomy radiot
Oncology March 30,2024
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

by St. Jude Children's Research HospitalCredit: Unsplash/CC0 Public DomainFibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The d
Oncology March 30,2024
Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

Immunotherapy targeting cancer fusion protein may hold key to treating rare liver cancer

by St. Jude Children's Research HospitalCredit: Unsplash/CC0 Public DomainFibrolamellar carcinoma (FLC) is a rare liver cancer with a poor prognosis if not addressed early with surgery. The d
Oncology March 30,2024
AI-based app can help physicians find skin melanoma

AI-based app can help physicians find skin melanoma

by Karin Söderlund,Swedish Research CouncilGraph showing the relationships between the primary care physicians' (PCPs') reported degree of melanoma suspicion, final tumor diagnosis and t
Oncology March 30,2024
AI-based app can help physicians find skin melanoma

AI-based app can help physicians find skin melanoma

by Karin Söderlund,Swedish Research CouncilGraph showing the relationships between the primary care physicians' (PCPs') reported degree of melanoma suspicion, final tumor diagnosis and t
Oncology March 30,2024
Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

by Denise Heady,University of California, Los AngelesGraphical Abstract. Credit:Cell Reports Medicine(2024). DOI: 10.1016/j.xcrm.2024.101479A study by researchers at the UCLA Health
Oncology March 30,2024
Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

by Denise Heady,University of California, Los AngelesGraphical Abstract. Credit:Cell Reports Medicine(2024). DOI: 10.1016/j.xcrm.2024.101479A study by researchers at the UCLA Health
Oncology March 30,2024
Survival 21 percent a year after ICU discharge for blood cancer patients

Survival 21 percent a year after ICU discharge for blood cancer patients

by Elana GotkineFor hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study published onl
Oncology March 30,2024
Survival 21 percent a year after ICU discharge for blood cancer patients

Survival 21 percent a year after ICU discharge for blood cancer patients

by Elana GotkineFor hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study published onl
Oncology March 30,2024
New bioinformatics tool to identify chromosomal alterations in tumor cells

New bioinformatics tool to identify chromosomal alterations in tumor cells

by University of BarcelonaRepresentative output image generated by QATS in which two toroidal nuclei (in magenta) and four micronuclei (in green) were identified. Credit:Bioinformatics&nbsp
Oncology March 30,2024
New bioinformatics tool to identify chromosomal alterations in tumor cells

New bioinformatics tool to identify chromosomal alterations in tumor cells

by University of BarcelonaRepresentative output image generated by QATS in which two toroidal nuclei (in magenta) and four micronuclei (in green) were identified. Credit:Bioinformatics&nbsp
Oncology March 30,2024
Why do cancer patients lose weight? Study points to elevated lactate levels

Why do cancer patients lose weight? Study points to elevated lactate levels

byNature Publishing GroupSchematic illustration depicting the signaling cascade downstream of lactate/GPR81 in promoting cancer cachexia. Credit:Nature Metabolism(2024). DOI: 10.1038
Oncology March 30,2024
Why do cancer patients lose weight? Study points to elevated lactate levels

Why do cancer patients lose weight? Study points to elevated lactate levels

byNature Publishing GroupSchematic illustration depicting the signaling cascade downstream of lactate/GPR81 in promoting cancer cachexia. Credit:Nature Metabolism(2024). DOI: 10.1038
Oncology March 30,2024
Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

by Polish Academy of SciencesOpto-hydrodynamic tweezers. (a) and (b) Schematic illustrations of the top view and side view of OHT, respectively, along with the major various forces acting on the
Oncology March 30,2024
Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

by Polish Academy of SciencesOpto-hydrodynamic tweezers. (a) and (b) Schematic illustrations of the top view and side view of OHT, respectively, along with the major various forces acting on the
Oncology March 30,2024
Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

by Science China PressSchematic illustration of the construction of conjugates I and II. Schematic illustration of the combinational effects on tumors of the PtIV-MSA-2 conjugates. The PtIV-MSA-2
Oncology March 30,2024
Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

by Science China PressSchematic illustration of the construction of conjugates I and II. Schematic illustration of the combinational effects on tumors of the PtIV-MSA-2 conjugates. The PtIV-MSA-2
Oncology March 30,2024
Mortality among low-risk differentiated thyroid cancer survivors in the US

Mortality among low-risk differentiated thyroid cancer survivors in the US

by Kathryn Ryan,Mary Ann Liebert, IncFlowchart of the study population. Credit:Thyroid(2023). DOI: 10.1089/thy.2023.0449A new study has shown that overall and cause-specific mortalit
Oncology March 30,2024
Mortality among low-risk differentiated thyroid cancer survivors in the US

Mortality among low-risk differentiated thyroid cancer survivors in the US

by Kathryn Ryan,Mary Ann Liebert, IncFlowchart of the study population. Credit:Thyroid(2023). DOI: 10.1089/thy.2023.0449A new study has shown that overall and cause-specific mortalit
Oncology March 30,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com